Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis

Yang,Jinsheng; Xiao,Zheng; Li,Tao; Gu,Xuanmin; Fan,Bo

doi:10.3892/ijo.2011.1261

Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis

Authors:
- Jinsheng Yang
- Zheng Xiao
- Tao Li
- Xuanmin Gu
- Bo Fan
View Affiliations

Affiliations: Department of Neurosurgery, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, P.R. China, Department of Neurosurgery, the First Affiliated Hospital of Henan University of Science and Technology, Jinghua Road 24, Luoyang 471003, P.R. China
Published online on: November 11, 2011 https://doi.org/10.3892/ijo.2011.1261
Pages: 1230-1237

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

rhEPO is frequently used in clinical practice to treat anemia. However, recently rhEPO has been reported to accelerate tumor growth, progression and metastasis. Many pituitary adenoma patients, particularly those with macroprolactinomas, tend to have anemia and may need rhEPO therapy. To date, whether rhEPO has deleterious effects on pituitary adenomas has not been defined. Here we demonstrated for the first time that human pituitary adenomas are EPOR negative tumors and rhEPO accelerated the tumor growth of MMQ pituitary adenoma xenografts via enhancement of angiogenesis in vivo, whereas rhEPO displayed no direct effect on MMQ cells in vitro. Our mechanistic study showed that rhEPO administration increased phosphorylation of JAK2, STAT3 and VEGF expression in human umbilical vein endothelial cells (HUVECs) in vitro and in MMQ cell xenografts in vivo. Furthermore, VEGF inhibitor attenuated rhEPO induced angiogenesis and delayed tumor growth in MMQ pituitary adenoma xenografts in vivo. JAK2 inhibitor AG490 attenuated EPO induced HUVECs proliferation, phosphorylation of JAK2, STAT3 and VEGF upregulation in vitro and inhibited EPO induced vessel formation in Chicken chorioallantoic membrane (CAM) angiogenesis model in vivo. These results suggest that rhEPO administration may promote the growth of pituitary adenomas by enhancing angiogenesis through EPO-JAK2-STAT3-VEGF signaling pathway. rhEPO should be used with caution in anemia patients bearing pituitary adenoma due to its potential deleterious effects.

View Figures

View References

1	Ng T, Marx G, Littlewood T and Macdougall I: Recombinant erythropoietin in clinical practice. Postgrad Med J. 79:367–376. 2003. View Article : Google Scholar
2	Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 4:459–460. 2003. View Article : Google Scholar : PubMed/NCBI
3	Henke M, Laszig R, Rube C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 362:1255–1260. 2003. View Article : Google Scholar
4	Jelkmann W, Bohlius J, Hallek M and Sytkowski AJ: The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol. 67:39–61. 2008. View Article : Google Scholar : PubMed/NCBI
5	Glaspy JA: Erythropoiesis-stimulating agents in oncology. J Natl Compr Cancer Netw. 6:565–575. 2008.
6	Glaspy J, Crawford J, Vansteenkiste J, et al: Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 102:301–315. 2010. View Article : Google Scholar : PubMed/NCBI
7	Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 23:5960–5972. 2005. View Article : Google Scholar
8	Temkin SM, Hellmann M, Serur E, Lee YC and Abulafia O: Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation. Int J Gynecol Cancer. 16:1855–1861. 2006. View Article : Google Scholar
9	Wright JR, Ung YC, Julian JA, et al: Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 25:1027–1032. 2007. View Article : Google Scholar : PubMed/NCBI
10	Smith RE Jr, Aapro MS, Ludwig H, et al: Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 26:1040–1050. 2008. View Article : Google Scholar
11	Thomas G, Ali S, Hoebers FJ, et al: Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dl with erythropoietin vs above 10.0 g/dl without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 108:317–325. 2008. View Article : Google Scholar
12	Lee YS, Vortmeyer AO, Lubensky IA, et al: Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res. 11:1059–1064. 2005.PubMed/NCBI
13	Saintigny P, Besse B, Callard P, et al: Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res. 13:4825–4831. 2007. View Article : Google Scholar : PubMed/NCBI
14	Lai SY, Childs EE, Xi S, et al: Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene. 24:4442–4449. 2005. View Article : Google Scholar : PubMed/NCBI
15	Arcasoy MO, Amin K, Vollmer RT, Jiang X, Demark-Wahnefried W and Haroon ZA: Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol. 18:421–430. 2005. View Article : Google Scholar : PubMed/NCBI
16	Jeong JY, Feldman L, Solar P, Szenajch J and Sytkowski AJ: Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int J Cancer. 122:274–280. 2008. View Article : Google Scholar : PubMed/NCBI
17	Acs G, Acs P, Beckwith SM, et al: Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 61:3561–3565. 2001.PubMed/NCBI
18	Ellegala DB, Alden TD, Couture DE, Vance ML, Maartens NF and Laws ER Jr: Anemia, testosterone, and pituitary adenoma in men. J Neurosurg. 98:974–977. 2003. View Article : Google Scholar : PubMed/NCBI
19	Shimon I, Benbassat C, Tzvetov G and Grozinsky-Glasberg S: Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression. Pituitary. 14:11–15. 2011. View Article : Google Scholar : PubMed/NCBI
20	Aron DC, Tyrrell JB and Wilson CB: Pituitary tumors. Current concepts in diagnosis and management. West J Med. 162:340–352. 1995.PubMed/NCBI
21	Ribatti D: Erythropoietin and tumor angiogenesis. Stem Cells Dev. 19:1–4. 2010. View Article : Google Scholar
22	Funamoto M, Fujio Y, Kunisada K, et al: Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem. 275:10561–10566. 2000. View Article : Google Scholar : PubMed/NCBI
23	Szenajch J, Wcislo G, Jeong JY, Szczylik C and Feldman L: The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review. Biochim Biophys Acta. 1806:82–95. 2010.PubMed/NCBI
24	Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP and Dewhirst MW: Erythropoietin biology in cancer. Clin Cancer Res. 12:332–339. 2006. View Article : Google Scholar : PubMed/NCBI
25	Mohyeldin A, Lu H, Dalgard C, et al: Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia. 7:537–543. 2005. View Article : Google Scholar : PubMed/NCBI
26	Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K and Arai H: Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia. 10:932–939. 2008.PubMed/NCBI
27	Ribatti D, Vacca A, Roccaro AM, Crivellato E and Presta M: Erythropoietin as an angiogenic factor. Eur J Clin Invest. 33:891–896. 2003. View Article : Google Scholar : PubMed/NCBI
28	Ribatti D, Poliani PL, Longo V, Mangieri D, Nico B and Vacca A: Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology. 50:636–641. 2007. View Article : Google Scholar : PubMed/NCBI
29	Anagnostou A, Lee ES, Kessimian N, Levinson R and Steiner M: Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA. 87:5978–5982. 1990. View Article : Google Scholar : PubMed/NCBI
30	Hardee ME, Cao Y, Fu P, et al: Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One. 2:e5492007. View Article : Google Scholar : PubMed/NCBI
31	Asaumi Y, Kagaya Y, Takeda M, et al: Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation. 115:2022–2032. 2007. View Article : Google Scholar : PubMed/NCBI
32	Osugi T, Oshima Y, Fujio Y, et al: Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J Biol Chem. 277:6676–6681. 2002. View Article : Google Scholar : PubMed/NCBI
33	Hilfiker-Kleiner D, Limbourg A and Drexler H: STAT3-mediated activation of myocardial capillary growth. Trends Cardiovasc Med. 15:152–157. 2005. View Article : Google Scholar : PubMed/NCBI